A thorough guide for readers to quickly gain an update on standard diagnosis and treatment methods for axial spondyloarthritis. Approximately 80 illustrations and images are used throughout the text to exemplify the disease and diagnostic and treatment algorithms. Easily accessible text and tables review the current treatment recommendations and emerging treatment options based on recent clinical trials.

The aim of this book is to return to the biomimicry and medicinal potential that inspired many of the early supramolecular chemists and to set it in the context of current advances in the field. Following an overview of supramolecular chemistry, the first section considers the efforts made to synthesize artificial systems that mimic biological entities. The second section addresses the application of supramolecular principles to molecular diagnostics with a particular emphasis on the 'receptor-relayreporter' motif. Many of the examples chosen have clinical importance. The third section takes the clinical diagnostic theme further and demonstrates the therapeutic applications of supramolecular chemistry through photodynamic therapy, drug delivery, and the potential for synthetic peptides to form antibiotic tubes. The short epilogue considers the potential for supramolecular solutions to be found for further challenges in biomimetic and therapeutic chemistry.

The biologics market continues to witness an impressive rate of growth and the monoclonal antibody market, in particular, has contributed remarkably to the expansion of this segment within the pharmaceutical industry. In 2006, close to 80% of the annual biologics growth rate in the United States (US) was attributed to cancer and anti-TNF antibodies, with increases in growth of 56% and 25%, respectively, compared to those in the previous year. Additionally, the monoclonal antibody sector is anticipated to achieve a growth rate of approximately 14% by 2012, easily outstripping the predicted 0.6% growth rate in the small molecules market. The robust late-stage antibody pipeline within the biotech sector has drawn an increasing amount of interest from the large pharmaceutical industry and has triggered the largest product and platform deals in 2006, with values more than $2.1 and $5.1 billion in partnering and mergers and acquisitions, respectively. Additionally, with the forthcoming emergence of biogenerics, next-generation bio-improved antibodies have drawn much attention and increasingly contribute to the growth of the biologics segment. As next-generation monoclonal antibodies confront their first-generation rivals, it is critical that these next-generation products offer a clear differentiating advantage against the existing competition. Successful strategies for the development of monoclonal antibodies require integration of knowledge with respect to target antigen properties, antibody design criteria such as affinity, isotype selection, Fc domain engineering, pharmacokinetic and pharmacodynamic (PK/PD) properties, antibody cross-reactivity across species, market differentiation opportunities for the first- and next-generation leads, and regulatory requirements from the early stages of antibody development. Biophysical measurements are one of the critical components necessary for the design of effective translational strategies for lead selection and evaluation of relevant animal species for preclinical safety and efficacy studies. Incorporation of effective translational strategies from the early stages of the antibody development process is a necessity, and when considered, it not only reduces development time and cost, but also fosters implementation of rational decision-making throughout all phases of antibody development. Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the unit dose and unit effect with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective and novel next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in relevant animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of bio-improved antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics."

B. R. Buckley and H. Heaney: Mechanistic Investigations of Copper(I)- Catalyzed Alkyne-Azide Cycloaddition Reactions.- J. D. Crowley and D. A. McMorran: "Click-Triazole" Coordination Chemistry: Exploiting 1,4-Disubstituted-1,2,3-Triazoles as Ligands.- S. Lee and A. H. Flood: Binding Anions in Rigid and Reconfigurable Triazole Receptors.- M. Watkinson: Click Triazoles as Chemosensors.- H.-F. Chow, C.-M. Lo and Y. Chen: Triazole-Based Polymer Gels.- T. Zheng, S. H. Rouhanifard, A. S. Jalloh, P. Wu: Click Triazoles for Bioconjugation.- S. Mignani, Y. Zhou, T. Lecourt and L. Micouin: Recent Developments in the Synthesis 1,4,5-Trisubstituted Triazoles.

G. Sandford: Perfluoroheteroaromatic Chemistry: Multifunctional Systems from Perfluorinated Heterocycles by Nucleophilic Aromatic Substitution Processes.- A. A. Gakh: Monofluorinated Heterocycles.- R. Dembinski Y. Li D. Gundapuneni A. Decker: Synthesis of beta-Halofurans.- Y. Shermolovich S. Pazenok: Synthesis of halogenated 5- and 6-membered sulfur- and Sulfur, Nitrogen Containing Heterocycles.- S. Minakata Y. Takeda J. Hayakawa: Heterocyclic Reagents Containing Nitrogen-Halogen Bond: Recent Applications.- Michael Schnurch: Recent Progress on the Halogen Dance Reaction on Heterocycles.- T. Kosjek E. Heath: Halogenated Heterocycles as Pharmaceuticals.- E. Heath T. Kosjek: Sources, Occurrence and Fate of Halogenated Heterocyclic Pharmaceuticals in the Environment.- J. Iskra: Green Methods in Halogenation of Heterocycles."

This book approaches the subject from a mechanistic perspective that pitches the language at a level that is understandable to those entering the field and who are not familiar with its common phrases or complex terms. It provides a simple encapsulation of concepts and expands on them. In each chapter the basic concept is explained as simply and clearly as possible without a great deal of detail, then in subsequent sections additional material, exceptions to the general rule, examples, etc., is introduced and built up. Such material was generously supplemented with diagrams; conceptually elegant line diagrams in two or three colors. The artwork was well thought out and able to condense the scientific principles into a novel and visually exciting form. The diagrams encourage browsing or draw the reader to salient points. In addition, the technique of highlighting key concepts in a separate box is used throughout each chapter.

Polycyclic hydrocarbons are of interest in many fields of science: theoretical chemistry, physical chemistry, organic chemistry, dyestuff chemistry and biology. With regard to the latter, I am indebted to Dr. Regina Schoental of the Medical Research Council for the review in this present work of carcinogenesis by polycyclic hydrocarbons. This book is designed to present the facts in a simple and clear order and to derive empirical rules from them, but it does not present a com prehensive theory about polycyclic hydrocarbons. An attempt is made instead to extend classical symbolism into modern structural chemistry. Thus extensive use is made of Robinson's aromatic sextet, which is applied in an uncompromising and strict way. This quasi-classical attempt is encouraged further by such completely unexpected dis coveries as those of Dewar benzene and of the electronic asymmetry of formally symmetric hydrocarbons. How difficult it is to break away from any established way of thinking has been admirably expressed by Kekule ("Organische Chemie," 1861, Part 1, page 4, translated from the German): "All our ideas are based, to an extent much greater than we ordinarily believe, on those of our predecessors. Our accumulated experience, the notions of which our training has accustomed us to, of whatever kind they have been, influence the course of our thoughts far more than we are willing to admit; only too frequently the following of our regularly used, well trodden way of thinking leads us to overlook the simplest of correlations."

Polycyclic hydrocarbons are of interest in many fields of science: theoretical chemistry, physical chemistry, organic chemistry, dyestuff chemistry and biology. With regards to the latter, I am indebted to Dr. Regina Schoental of the Medical Research Council for the review in this present work of carcinogenesis by polycyclic hydrocarbons. This book is designed to present the facts in a simple and clear order and to derive empirical rules from them, but it does not present a com prehensive theory about polycyclic hydrocarbons. An attempt is made instead to extend classical symbolism into modern structural chemistry. Thus extensive use is made of Robinson's aromatic sextet, which is applied in an uncompromising and strict way. This quasi-classical attempt is encouraged further by such completely unexpected dis coveries as those of Dewar benzene and of the electronic asymmetry of formally symmetric hydrocarbons. How difficult it is to break away from any established way of thinking has been admirably expressed by Kekule ("Organische Chemie," 1861, Part 1, page 4, translated from German): "All our ideas are based, to an extent much greater than we ordinarily believe, on those of our predecessors. Our accumulated experience, the notions of which our training has accustomed us to, of whatever kind they have been, influence the course of our thoughts far more than we are willing to admit; only too frequently the following of our regularly used, well trodden way of thinking leads to us overlook the simplest of correlations."

The field of DNA vaccines has undergone explosive growth in the last few years. As usual, some historical precursors of this approach can be d- cerned in the scientific literature of the last decades. However, the present state of affairs appears to date from observations made discreetly in 1988 by Wolff, Malone, Felgner, and colleagues, which were described in a 1989 patent and published in 1990. Quite surprisingly, they showed that genes carried by pure plasmid DNA and injected in a saline solution, hence the epithet "naked DNA," could be taken up and expressed by skeletal muscle cells with a low but reproducible frequency. Such a simple methodology was sure to spawn many applications. In a separate and important line of experimentation, Tang, De Vit, and Johnston announced in 1992 that it was indeed possible to obtain humoral immune responses against proteins encoded by DNA delivered to the skin by a biolistic device, which has colloquially become known as the "gene gun. " The year 1993 saw the publication of further improvements in the me- ods of naked DNA delivery and, above all, the first demonstrations by several groups of the induction of humoral and cytotoxic immune responses to viral antigens expressed from injected plasmid DNA. In some cases, protection against challenge with the pathogen was obtained. The latter result was - questionably the touchstone of a method of vaccination worthy of the name.

This Adis Pocket Reference presents an up-to-date, succinct, and practical approach to drug therapy for type 2 diabetes.

Combinatorial chemistry and molecular diversity approaches to scientific inquiry and novel product R&D have exploded in the 1990s! For example, in the preparation of drug candidates, the automated, permutational, and combinatorial use of chemical building blocks now allows the generation and screening of unprecedented numbers of compounds. Drug discovery - better, faster, cheaper? Indeed, more compounds have been made and screened in the 1990s than in the last hundred years of pharmaceutical research. This first volume covers: (i) combinatorial chemistry, (ii) combinatorial biology and evolution, and (iii) informatics and related topics. Within each section chapters are prepared by experts in the field, including, for example, in Section I: Coverage of mixture pools vs. parallel individual compound synthesis, solution vs. solid-phase synthesis, analytical tools, and automation. Section II highlights selection strategies and library-based evolution, phage display, peptide and nucleic acid libraries. Section III covers databases and library design, high through-put screening, coding strategies vs. deconvolutions, intellectual property issues, deals and collaborations, and successes to date.

This classic work by Poucher, first published in 1923, was last produced in three volumes titled, respectively The Raw Materials of Perfumery (seventh edition, 1974), The Production, Manufacture and Application of Perfumes (eighth edition, 1974) and Modern Cosmetics (eighth edition, 1974). Its popularity is well demonstrated by there having been three reprints of these editions in 1976, 1979 and 1984, res pecti vel y . The history of events can be traced by reference to the prefaces to earlier editions and those interested should study these with care since they give a fascinating insight into developments in the subject fields covered by Poucher's Perfumes, Cosmetics and Soaps over the years. It is not proposed to provide a resume here. In this Volume I, the current edition attempts to provide data about raw materials in a more formalized way than before, so that not only the history of some compounds can be checked, but also so that useful reference information can be obtained. It is particularly relevant to do this, since it is not always easy to be certain of nomenclature. Moreover, as we move towards 'ingredient labelling' (a trend not welcomed by some), a high level of uniformity will be needed. Whether this will come from adoption of CTFA terminology, use of CAS numbers or some other system is not clear. Where possible, such data have been included so that readers may identify materials more readily. Where given, CAS numbers are located in the top right-hand corner of each entry.

Advances in understanding the molecular mechanisms of disease together with the advent of recombinant DNA and other technologies have opened opportunities for a vast array of novel therapeutic biopharmaceuticals and diagnostic agents. However, even natural biomolecules present a myriad of problems that limit their potential as pharmaceutical agents. Rapid degra- tion and elimination, immunological reactions, and toxicity are often asso- ated with new biopharmaceuticals, much as with conventional agents. Targeted delivery systems have the potential to increase the efficacy of existing diagnostic and therapeutic agents and also create an opportunity for the use of new pharmaceuticals, substances that themselves can be harmful to normal tissues. Both passive and active targeting have been exploited. Most active targ- ing strategies have focused on antibody conjugates since preparation of highly specific monoclonal antibodies is well established. However, a new wave of c- jugates exploiting other ligands is underway. Access to the target tissue remains an obstacle and is an area where passive targeting can be useful. In Drug Targeting: Strategies, Principles, and Applications we have tried to compile a state-of-the-art volume on current targeting approaches. The first section focuses on certain key strategies applied to date, and how to build the antibody- ligand constructs. This is followed by a section on theoretical considerations for t- geting, focusing on approaches relevant to solid tumors. The last section deals with some experimental and clinical applications of targeted drug delivery systems.

This volume summarizes current research on the influence of plant polyphenols on human health, promoting collaboration between chemists and biologists to improve our understanding of their biological significance, and expanding the possibilities for their use.

Pharmaceutical scientists in industry and academia will appreciate this single reference for its detailed experimental procedures for conducting biopharmaceutical studies. This well-illustrated guide allows them to establish, validate, and implement commonly used in situ and in vitro model systems. Chapters provide ready access to these methodologies for studies of the intestinal, buccal, nasal and respiratory, vaginal, ocular, and dermal epithelium as well as the endothelial and elimination barriers.

Volume 4 of the Encyclopedia of the Alkaloids covers the literature to the end of 1981 and includes those compounds which have been discovered since Volume 3 was published in 1977. There is also a small number of entries giving recently determined structure or addi tional information regarding alkaloids given in the preceding three volumes. It is a great pleasure to thank the staff of the John Rylands Science Library of the Univer sity of Manchester for kindly providing me with access to the literature on this subject. Woodhouses, JOHN S. GLASBY Manchester, England May, 1982 Contents A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251 B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262 C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 273 0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 Q . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299 E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141 R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300 F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152 S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31O G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158 T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339 H . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167 U . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 358 I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192 V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361 J . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 W . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367 K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210 X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368 L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217 Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369 M . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227 Z . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 370 Formula Index. . . . . . . . . . . . . . . . . . . . 371 A ACETYLALLOYOHIMBINE (Alkaloid NRB6) C23H2SN203 M. p. Indefinite I I OAc The root bark of Rauwolfia nitida yields this yohimbine-type alkaloid which has been ob tained as an off-white amorphous powder having no definite melting point. The base is lae 2 vorotatory with a specific rotation of [aJ5 -89 Degrees (c 0. 01, CHCI ) and gives an ultraviolet 3 spectrum in MeOH with absorption maxima at 225,284 and 290 nm. The structure has been established from chemical and spectroscopic analysis. M. A. Amer, W. E. Court, Phytochem. , 20,2569 (1981) 14-ACETYLBROWNINE ___ :(OMe M. p.

In the pharmaceutical industry, the incorporation of the disciplines of pharma- kinetics, pharmacodynamics, and drug metabolism (PK/PD/DM) into various drug development processes has been recognized to be extremely important for approp- ate compound selection and optimization. During discovery phases, the identifi- tion of the critical PK/PD/DM issues of new compounds plays an essential role in understanding their pharmacological profiles and structure-activity relationships. Owing to recent progress in analytical chemistry, a large number of compounds can be screened for their PK/PD/DM properties within a relatively short period of time. During development phases as well, the toxicology and clinical study designs and trials of a compound should be based on a thorough understanding of its PK/PD/DM properties. During my time as an industrial scientist, I realized that a reference work designed for practical industrial applications of PK/PD/DM could be a very valuable tool for researchers not only in the pharmacokinetics and drug metabolism departments, but also for other discovery and development groups in pharmaceutical companies. This book is designed specifically for industrial scientists, laboratory assistants, and managers who are involved in PK/PD/DM-related areas. It consists of thirteen chapters, each of which deals with a particular PK/PD/DM issue and its industrial applications. Chapters 3 and 12 in particular address recent topics on higher throughput in vivo exposure screening and the prediction of pharmacokinetics in humans, respectively. Chapter 8 covers essential information on drug metabolism for industrial scientists.

This volume was planned to provide a comprehensive survey of the role of the anabolic-androgenic steroids in the vital economy exclusive of the androgenic (sexual) functions. It seemed appropriate to bring together all of this information in an organized fashion in one volume at this time not only to serve as a source of information but also to indicate and suggest areas that need further exploration. The anabolic action of the steroid hormones has gone through a period of great activity in both basic and clinical research. A complete understanding of the manifold anabolic effects still remains to be elucidated and the art of clinical application is only gradually becoming apparent. This volume should be useful not only to the experienced investigator in both basic and clinical research but also for the novice. Furthermore, it should serve as a source of information for the careful use of these steroids in certain metabolic diseases. These steroids have had wide clinical application with variable results. In many instances further careful exploration is suggested. Other instances have demonstrated varying degrees of usefulness.

"Der wichtigste Schritt in der Fortentwicklung aller Naturwissenschaften ist mit der Einfuhrung der Messung von Grossen gemacht worden. " (J. C. MAXWELL, Theorie der Warme, Dt. uber- setzung nach der 4. Aufl. , 1877) Die Analyse des Elektrolyt- und Wasserhaushaltes bei Patienten mit generali- sierten Odemen hat ergeben, dass die Unfahigkeit des Organismus, die mit der Nahrung zugefuhrten Natriumionen quantitativ zu eliminieren, ein gemeinsames Merkmal dieser Erkrankungen ist. Die Ansammlung von Wasser im extracellularen Raum ist lediglich die Folge dieser Natriumretention. Der Anteil der Niere an der Entstehung solcher Storungen des Elektrolyt- und Wasserhaushalts beruht auf der I mbalance glomerular-tubularer Funktionen, die renale und extrarenale Ursachen haben kann. Die Minderung der glomerularen Filtration ist fur die Entstehung der Odeme sicher von geringerer Bedeutung als die zu intensive Ruckgewinnung des Primarharns unter den pathologischen Bedingungen, die den Ausgleich der gestorten Salz- und Wasserbilanz verhindert. Prinzipiell kann eine Vermehrung der Harnausscheidung sowohl durch Ver- grosserung der glomerularen Filtration als auch durch Hemmung der tubularen Ruckgewinnung des Primarharns erreicht werden. Die heute gebrauchlichen Diuretica verandern ganz uberwiegend tubulare Funktionen und beeinflussen daher den an zweiter Stelle genannten Prozess.

Bioinformatics brings computational methods to the analysis and processing of genomic data. Bioinformatics: Databases and Systems focuses on the issues of system building and data curation that dominate the day-to-day concerns of bioinformatics practitioners. Included are chapters by many of today's leading bioinformatics practitioners, describing most of the current paradigms of system building and curation, including both their strengths and weaknesses. Biological topics covered include sequence databases, metabolic pathways, phenotypes, variety collections, gene expression atlases and neuroinformatics. Species range from bacteria to mammals to plants. Software systems and technologies covered include OPM, CORBA, SRS, KLEISLI, ACEDB, Web-based integration and laboratory workflow. Bioinformatics: Databases and Systems provides a valuable introduction for newcomers to the field, and a useful reference for veterans.

Consumer interest in diet and nutritional supplements is increasing dramatically. Patients and members of the public are seeking advice from health professionals, nutritionists and food scientists. This book is designed to meet the needs of those professionals who are called upon to advise patients and the general public. It provides also a valuable text for those who are researchers or decision makers in the food and pharmaceutical industries. The text presents a thorough account of this topical subject and enables the reader to appreciate the functions of nutrients in health and common disease states, to understand the current debates over the roles of nutrients and supplements in the diet, and to answer those questions frequently asked by patients and consumers.